Takeda chief executive officer, christophe weber, commented “takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of. What's going on at takeda pharmaceutical (nyse:tak) Read today's tak news from trusted media outlets at marketbeat. Takeda pharmaceutical (tse:4502) shares have seen subtle moves recently, and investors are weighing the outlook as the market absorbs ongoing developments in japan’s pharmaceutical sector See our latest analysis for takeda pharmaceutical
Takeda’s shares have kept investors guessing this year, with momentum pausing despite upbeat clinical. For more information, visit www.takeda.com Takeda pharmaceutical has announced it will discontinue all cell therapy research and development, marking a significant strategic withdrawal from a field it once considered a priority area for innovation. More than 130 employees in massachusetts will be laid off from takeda pharmaceuticals next year, as the company discontinues its cell therapy efforts, a spokesperson confirmed.
OPEN
